ClinicalTrials.gg
CompletedNCT03918798Updated Mar 23, 2026

The Efficacy and Safety of Chloroprocaine 1% and 2% in Pediatric Population

A Phase 2 interventional study of Chloroprocaine 1% Injectable Solution and Chloroprocaine 2% Injectable Solution in Hernia, Inguinal and Flat Foot, sponsored by Sintetica SA. Completed at 9 sites in 2 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Sintetica SA · Phase 2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Hernia, Inguinal with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Hernia, Inguinal · Italy.

Enrollment
5th of 14
164 · median 116
Started
2019
with 3 others
Phase 2
Only one
of the 19
Registered
10th of 19
by date

Among the 19 studies in Hernia, Inguinal with a site in Italy, this one is the 5th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2019, is the only one in phase 2, and was the 10th registered.

Hernia, Inguinal

545 studies on the registry are indexed under Hernia, Inguinal; 93 are open to participants now.

Browse Hernia, Inguinal studies →

Open to participants now

3 of the 19 studies in Hernia, Inguinal with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 56 Hernia, Inguinal studies recruiting now, 30 (54%) set no upper age limit and 17 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Hernia, Inguinal with a site in Italy, or all of them as a file.
02

Study summary

Randomized, multi-center, double-blind, two-armed, parallel active groups, prospective trial to evaluate the efficacy and safety of local anesthetic Chloroprocaine at two different concentrations ( at 1% and 2%) in a pediatric population subjected to peripheral nerve block due to Inguinal hernia repair or Flat foot surgery. The present Protocol is part of an extensive Pediatric Investigational Plan (PIP) in the contest of the marketing authorization application of chloroprocaine use for perineural block. The PDCO has adopted a positive opinion.

Read the detailed description

Randomized, multi-center, double-blind, two-armed, parallel active groups, prospective trial, to evaluate, in pediatric population undergoing Flat Foot surgery or Inguinal hernia repair, the efficacy and safety of chloroprocaine 1% and 2% for peripheral nerve block (PNB) based on concentration-response relationships. The present protocol is part of an extensive Pediatric Investigational Plan (PIP) which has been submitted to the Paediatric Committee (PDCO) of the European Medicine Agency (EMA)in the contest of the marketing authorization application of chloroprocaine use for perineural block. The PDCO has adopted a positive opinion on both the PIP and the present clinical protocol.

Chloroprocaine Hydrochloride 1% Sintetica is currently marketed in 9 European countries as intrathecal (spinal) anesthetic in adults where the planned surgical procedure is not expected to exceed 40 minutes. Since 2015, the Marketing Authorization in Switzerland has been extended to chloroprocaine HCl 20 mg/mL and 30 mg/mL solutions for injection, for local anesthesia by infiltration, for PNB and epidural block, respectively. Regional analgesia, and specifically PNB, is an acceptable means of providing intraoperative anesthesia and postoperative analgesia in neonates, infants, and children while decreasing the use of systemic opioids and avoiding opioid-related adverse effects. With the advent of ultrasound and improvements in equipment in the last decade, the utilization of PNB in children has increased tremendously.

Flat Foot and inguinal hernia repair have been considered the ideal surgeries for testing the clinical efficacy and safety of chloroprocaine since they are short procedures with low postoperative pain that only require a short- to intermediate-acting agent. The study consists of a treatment period of 1 day and of a single perineural injection, administered through ultrasound-guided technique in order to avoid the risk of chloroprocaine IV injection. A total of 174 (87 per treatment group, allocated to 1% or 2% arm in a ratio of 1:1) male and female paediatric patients (age range from birth to \<18 years) undergoing Flat Foot surgery or Inguinal hernia repair, planned for peripheral nerve block anaesthesia and equally distributed within the two surgical procedures.

03

Conditions studied

  • Hernia, Inguinal
  • Flat Foot

Keywords

  • Surgery
  • Hernia, Inguinal
  • Flat Foot
  • Pediatric population
  • Peripheral nerve block
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female paediatric patients from birth to \<18 years scheduled for:

    • Flat Foot surgery (6 to \<18 years; children and adolescents)planned for sciatic nerve block short-lasting anaesthesia,
    • inguinal hernia repair (28 day from birth to 6 years; infants-toddlers and children)planned for ilioinguinal/iliohypogastric block short-lasting anaesthesia;
  2. Normally active and otherwise judged to be in good health on the basis of medical history, physical examination, with normal lean body mass (BMI18,5 - 24,9 Kg/m2 inclusive) and normal body development (normal weight and height according to local paediatric Height and Weight Chart);
  3. and ASA II patients;
  4. Written provided by parents/tutor, willing and able to understand the purpose of the study, including possible risks and side effects, and willing and able to comply, on their behalf and of the minor, with the study requirements;
  5. Willing and able to give additional written informed consent by itself, in case of children and adolescents, in addition to parents/tutor;
  6. Willing and able, in case of children and adolescents, to comply with the study requirements on their behalf.

Exclusion criteria

Exclusion Criteria:

  1. ASA > II patients;
  2. Preexistent infection at injection site;
  3. Use of opioids, antidepressants, anticonvulsant, sulfonamide, vasopressors, ergot-type oxytocic drug and mixtures of local anaesthetics, antiarrhythmic drug class III, such as amiodarone, strong inhibitors of CYP1A2, such as fluvoxamine and enoxacin;
  4. Use of medication(s) known to interfere with the extent of regional blocks for 2 weeks before the start of the study;
  5. History of drug or alcohol abuse;
  6. Sensitivity among the study medication active ingredient, the members of the PABA esters group and amides-type local anesthetic group;
  7. Clinical history of allergy, or intolerance to the study medication or other medications used during surgery;
  8. Pregnancy and lactation: positive pregnancy test at screening (if applicable), pregnant or lactating (the pregnancy test will be performed to all fertile subset);
  9. Participation in any other clinical study within the 3 months prior to the screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    Chloroprocaine 1%

    All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.

    Drug: Chloroprocaine 1% Injectable Solution

  • Experimental
    Chloroprocaine 2%

    All the eligible patients will be administrated by Chloroprocaine 2 % according to the randomization criteria.

    Drug: Chloroprocaine 2% Injectable Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Overall proportion of patients, in each of the two dosage level groups, not requiring rescue anesthesia during surgery.

    The primary efficacy endpoint of the study will be represented by the overall proportion of patients, in each of the two dosage level groups, not requiring rescue anesthesia during surgery.

    Time frame: Visit 2 (Day 1; surgery/discharge)

Secondary outcomes

  1. Proportion of patients, in both of the two dosage level groups, not requiring rescue anaesthesia (fentanyl) during the two surgical procedures separately

    Proportion of patients, in both of the two dosage level groups, not requiring rescue anaesthesia (fentanyl) during the two surgical procedures separately; Time to onset of sensory block, defined as the time period from completion of the injection (time 0 min) to the achievement of complete sensory block, assessed by pinprick test associated with heart rate measurement, and evaluated for both surgeries; Time to regression of motor block evaluated in 'calcaneo stop' surgery only and assessed by a grade I of the standard Bromage scale (i.e. free movement of legs and feet). Pain intensity evaluated five times in the first 3 hours after patient's awakening andduring the home discharge visit (V2). The technique and appropriate scale for pain measurement are age-dependent therefore, different tools will have to be used for the evaluation: COMFORT scale for patients \<2 months of age; FLACC scale for patients aged \_ 2 months \_ 6 years; Wong-Baker scale for patients over 6 years of age

    Time frame: Visit 2 (Day 1; surgery/discharge); FU phone call I( 24 hrs from Visit 2); FU phone call II (7 days from Visit 2)

07

Study locations

9 sites
  • Ospedale Pediatrico Giovanni XXIII
    Bari, Italy 70126, Italy
  • ASST Gaetano Pini CTO
    Milan, Italy 20122, Italy
  • Ospedale Pediatrico Bambin Gesù di Roma Dipartimento di Emergenza Accettazione (DEA) e A.R.C.O
    Rome, Lazio 00165, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli U.O.C. Anestesia delle Chirurgie Generali del Policlinico
    Rome, Lazio 00168, Italy
  • Ospedale San Raffaele Anestesia e Rianimazione del distretto testacollo
    Milan, Lombardy 20132, Italy
  • Ospedale Infantile Santa Margherita di Torino Anestesia e Rianimazione Pediatrica
    Turin, Piedmont 10126, Italy
  • Ospedale Universitario Santa Maria della Misericordia S.C. di Anestesia e Rianimazione 2
    Perugia, Umbria 06129, Italy
  • Consorcio Hospital General Universitario De Valencia Cirugía Mayor Ambulatoria Y Cirugía General Y Del Aparato Digestivo
    Valencia, Valencia 46014, Spain
  • Hospital Universitario Y Politecnico La Fe Cirugía Pediátrica Avda. Fernando Abril
    Valencia, Valencia 46026, Spain
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — It is not yet known if there will be a plan to make IPD available.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Oct 2025, 80 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2019
First posted
Apr 18, 2019
StartActual
Feb 14, 2019
Primary completionActual
Oct 17, 2025
CompletionActual
Oct 17, 2025
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03918798
Lead sponsor
Sintetica SA
Responsible party
Sponsor
First posted
Apr 18, 2019
Start date
Feb 14, 2019
Primary completion
Oct 17, 2025
Completion
Oct 17, 2025
Last update
Mar 23, 2026

Study contacts

Valeria Mosetti, MD
principal investigator · Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chloroprocaine

Start the discussion